Drug Trial Radar · NCT07744386
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Dec 15, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a breast cancer resistant protein substrate) in healthy male participants.
Conditions
- Healthy Male Volunteers
Interventions
Dabigatran EtexilateDrug
Treatment period 1: Single dose administered on Day 1; Treatment period 2: Single dose administered on Day 13
RosuvastatinDrug
Treatment period 1: Single dose administered on Day 4; Treatment period 2: Single dose administered on Day 16
CHF10196Drug
Treatment period 2: Single dose administered daily from Day 8 to Day 19
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics of Dabigatran : AUC0-tTime frame: Up to 72 hours after dosing
- Pharmacokinetics of Dabigatran: AUC0-∞Time frame: Up to 72 hours after dosing
- Pharmacokinetics of Dabigatran: CmaxTime frame: Up to 72 hours after dosing
- Pharmacokinetics of Rosuvastatin :AUC0-tTime frame: Up to 96 hours after dosing
- Pharmacokinetics of Rosuvastatin : AUC0-∞Time frame: Up to 96 hours after dosing
- Pharmacokinetics of Rosuvastatin: CmaxTime frame: Up to 96 hours after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit (CRU) Limited
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.